tiprankstipranks
Tonix Pharma (TNXP)
NASDAQ:TNXP

Tonix Pharma (TNXP) Income Statement

2,373 Followers

Tonix Pharma Income Statement

Last quarter (Q3 2023), Tonix Pharma's total revenue was $3.99M, an increase of Infinity% from the same quarter last year. In Q3, Tonix Pharma's net income was $-27.98M. See Tonix Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 3.99M$ 7.77M--$ 0.00$ 0.00
Cost of Revenue
$ 2.37M$ 4.74M----
Gross Profit
$ 1.61M$ 3.03M----
Operating Expense
$ 57.59M$ 121.41M$ 112.09M$ 92.31M$ 50.51M$ 28.83M
Operating Income
$ -55.98M$ -118.38M$ -112.09M$ -92.31M$ -50.51M$ -28.83M
Net Non Operating Interest Income Expense
$ 2.76M$ 1.72M$ 1.87M$ 25.00K$ 48.00K$ 210.00K
Other Income Expense
-$ 283.00K----
Pretax Income
$ -50.84M$ -116.66M$ -110.22M$ -92.29M$ -50.46M$ -28.62M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -55.62M$ -116.66M$ -116.88M$ -92.29M$ -52.17M$ -31.09M
Basic EPS
$ -6.34$ -6.85$ -3.27$ -1.63$ -17.60$ -19.33
Diluted EPS
$ -6.34$ -6.85$ -3.27$ -1.63$ -17.60$ -19.33
Basic Average Shares
$ 125.01M$ 17.04M$ 35.74M$ 57.63M$ 2.96M$ 1.61M
Diluted Average Shares
$ 125.01M$ 17.04M$ 35.74M$ 57.63M$ 2.96M$ 1.61M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 59.96M$ 126.15M$ 112.09M$ 92.31M$ 50.51M$ 28.83M
Interest Expense
------
Net Income From Continuing And Discontinued Operation
$ -121.02M$ -116.66M$ -110.22M$ -92.29M$ -50.46M$ -28.62M
Normalized Income
$ -22.40M$ -92.16M--$ -50.46M$ -28.62M
EBIT
$ -54.43M$ -116.66M$ -110.22M$ -92.29M$ -50.51M$ -28.83M
EBITDA
$ -52.49M$ -112.37M$ -108.97M$ -92.24M$ -50.48M$ -28.80M
Currency in USD

Tonix Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis